This is the largest published record of what happens when these drugs are sold the way the sellers on this site sell them — online, by subscription, without a clinic. It is worth reading closely for exactly that reason, starting with who each number describes, because a headline cohort is rarely the group a figure was measured in.
The numbers, with their denominators
630,545 eligible patients, 80.3% of them women, mean body mass index 36.1. [1] At six months, mean weight loss among those with a recorded weight was 13.5%, 95% CI 13.51 to 13.56, in 270,309 people. At twelve months, 17.4%, 95% CI 17.3 to 17.5, in 58,434.
At six months, 89.9% had lost at least 5% and 72.1% at least 10% — again, among those who reported a weight.
Self-reported, by people paying for it
Weights came from patients entering them into the service, not from a clinic scale.
That is how a digital service has to work and it is a second selection on top of the first: reporting a weight is itself a behavior, and it correlates with the thing being measured. The association the authors found between regular ordering and greater weight loss has the same shape — engagement predicting outcome describes who engages at least as much as what engaging does.
The finding that is about money
Patients from less deprived areas placed 26.1% more prescription orders than those from the most deprived areas.
Persistence is the outcome that decides what a course actually costs and whether any of the weight stays off, and here it tracks postcode. That is the same gradient behind most eligible patients declining on price and behind income appearing among the predictors in the persistence literature.
The dose line, read carefully
The authors report that clinically meaningful outcomes were frequently achieved without escalation beyond intermediate doses.
That is an observation about who stayed where, not a recommendation. People who stop escalating are disproportionately people for whom the current dose is working, and the comparison is not randomized. What it does establish is that the intermediate rungs are where a lot of this market sits — which matters when a seller’s price changes as the dose climbs.
What a buyer takes from it
That 13.5% at six months is a real result for people who kept ordering and kept weighing, and that the cohort it came from is four times larger than the group it was measured in.
Both halves belong to anyone deciding whether to prepay for a term. The patient-reported benefits are worth having too — 46.7% reported better mobility, 45.9% better mood and 26.7% drinking less — and they come from the same survivors.